Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/235362
Type: Artigo
Title: Posicionamento sobre o uso de tofacitinibe no algoritmo do Consenso 2012 da Sociedade Brasileira de Reumatologia para o tratamento da artrite reumatoide
Title Alternative: Update on the 2012 brazilian society of rheumatology guidelines for the treatment of rheumatoid arthritis: position on the use of tofacitinib / QUANDO ABRE PDF, abre EM PORTUGUÊS.
Author: Mota
L.M.H.
Cruz, B.A.
Albuquerque, C.P.
Gonçalves, D.P.
Laurindo, L.M.M.
Pereira, I.A.
Carvalho, J.F.
Pinheiro, G.R.C.
Bertolo, M.B.
Pinto, M.R.C.
Louzada-, P.J.
Xavier, R.M.
Giorgi, R.D.N.
Lima,, R.A.C.
Abstract: In 2014, tofacitinib, a target-specific, synthetic disease modifying anti rheumatic drug (DMARD) and a selective inhibitor of Janus kinase (JAK) was approved for use in Brazil. This position paper aims to update the recommendations of the Brazilian Society of Rheumatology (SBR) on the treatment of rheumatoid arthritis (RA) in Brazil, specifically regarding the use of target-specific synthetic DMARDs. The method of this recommendation consisted of a literature review of scientific papers held on the Medline database. After this review, a text was produced, answering questions in Pico structure, considering efficacy and safety issues of tofacitinib use for RA treatment in different scenarios (such as first-line treatment after failure with methotrexate [MTX] or other conventional synthetic DMARDs after failure with biological therapy). Based on existing evidence, and considering the available data on efficacy, safety and cost of medications available to treat the disease in Brazil, the RA Commission of SBR, after a process of discussion and voting on proposals, established the following position on the use of tofacitinib for treatment of RA in Brazil: Tofacitinib, alone or in combination with MTX, is an alternative for RA patients with moderate or high activity after failure of at least two different synthetic DMARDs and one biological DMARD. The level of agreement with this recommendation was 7.5. This position may be reviewed in the coming years, in the face of a greater experience with the use of this medication.
Em 2014, o tofacitinibe, um medicamento modificador do curso da doença (MMCD) sintético, alvo‐específico, inibidor seletivo das Janus quinases (JAK), foi aprovado para uso no Brasil. Este documento de posicionamento tem o objetivo de atualizar as recomend
metadata.dc.description.abstractalternative: In 2014, tofacitinib, a target-specific, synthetic disease modifying anti rheumatic drug (DMARD) and a selective inhibitor of Janus kinase (JAK) was approved for use in Brazil. This position paper aims to update the recommendations of the Brazilian Societ
Subject: Metotrexato
Artrite reumatóide
Country: Brasil
Editor: Sociedade Brasileira de Reumatologia
Citation: Revista Brasileira De Reumatologia. v. 55, n. 6, p. 512-521
Rights: fechado
Identifier DOI: 10.1016/j.rbr.2015.08.004
Address: https://www.sciencedirect.com/science/article/pii/S0482500415001278
Date Issue: 2015
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
000365184800007.pdf787.09 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.